Biotech | February 23, 2022
Merck completes acquisition of biopharma CDMO Exelead
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
New inhalers would have near-zero Global Warming Potential propellant
Therapeutic use of the product is for short term symptomatic relief of colds, chills and influenza including chesty coughs
The transaction as well as the open offer is expected to be completed by June this year.
The sale is expected to close in the first quarter of 2022
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
Sputnik Light can become a major booster for those vaccinated with inactivated Chinese Covid-19 vaccines globally after China has officially recommended mix & match approach with adenoviral vector-based vaccines as boosters
CEPI is accelerating its programme to develop broadly protective coronavirus vaccines—a core part of US $ 3.5 billion pandemic preparedness plan
The company will now be allowed to sell its proprietary and validated tinctures, gummies, and capsules across the UK
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
Subscribe To Our Newsletter & Stay Updated
